PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)

por Hamadani, M., Linhares, Y., Gandhi, M. D., Chung, M., Adamis, H., Ungar, D., Carlo-Stella, C., Kingsley, E., Depaus, J., Snauwaert, S., Kwiatek, M., López-Jiménez, J.
Publicado 2022